Better Context → Better Decisions
Context counts in life sciences. The Celltelligence analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access can use our library to search all of the content already delivered to their inbox. If you think a colleague would enjoy receiving our content, reach out to the Celltelligence team to make it happen.
Free
Posted in: Autologous, CAR-T, CD19 Nov 29 | 2023Novartis to Rapidly Advance YTB323 in Autoimmune Diseases; Cell Therapy Evaluation in MS Could Be Initiated Soon; Novartis’s R&D Day SummaryAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19, Dual/triple agonist Nov 28 | 2023Autolus Submits Obe-cel BLA in R/R B-ALL; GC012F Receives IND Clearance in rSLEAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, Topics Nov 21 | 2023Abecma sBLA to Face FDA AdCom; PDUFA Date Delayed; Could Carvykti Be Approved Before Abecma in Earlier Lines of MM?Access Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Nov 21 | 2023CARTITUDE-6 to Start Recruiting Soon in the US; Legend’s Facility in Belgium Set to Start Clinical Trial Manufacturing; Legend’s Q3 2023 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Nov 16 | 2023Thoughts on the Expansion of Arcellx and Gilead Partnership; Gilead to Expand Scope of CART-ddBCMA to Lymphomas and Exercise Option to ACLX-001Access Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, TCR Nov 15 | 2023Abecma Revenue Decreases Significantly; bbT4015 IND on Track for YE 2023; JW Tx to Initiate JWTCR001’s IIT by YE 2023; 2seventy Bio’s Q3 2023 Earnings CallAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19, Dual/triple agonist Nov 14 | 2023GC012F's US Trial in MM Initiates Dosing; GC012F IND in SLE on Track for 2023; Gracell Initiates GC506 Clinical Development in Solid Tumors and Deprioritizes GC007g in B-ALL; Gracell’s Q3 2023 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, CAR-T Nov 14 | 2023Thoughts on Novartis’s Agreement with LegendAccess Free Blast
Free
Posted in: Allogeneic, BCMA, CAR-T Nov 13 | 2023Roche Collaboration Milestones and Payments Accelerated; P-MUC1C-ALLO1's Clinical Update Postponed to H1 2024; Poseida’s Q3 2023 Earnings SummaryAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Nov 10 | 2023Breyanzi sBLA for R/R CLL/SLL Receives FDA Priority ReviewAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Nov 10 | 2023Abecma T2V Receives a Second RSI; When Could Abecma and Carvykti Receive a Positive CHMP Opinion? November CHMP HighlightsAccess Free Blast
Free
Posted in: Allogeneic, Autologous, TCR, Topics Nov 09 | 2023Afami-cel BLA Submission on Track for YE 2023, Lete-cel IND Set to Transition from GSK by YE 2023; MSLN TRuC Programs Deprioritized; Adaptimmune to Advance PRAME Program to the Clinic in 2024; Adaptimmune’s Q3 2023 Earnings CallAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Nov 08 | 2023Gilead’s Cell Therapy Revenue Continues to Grow; Promising Results from CART-ddBCMA Expected at ASH 2023; Gilead’s Q3 2023 Earnings Call SummaryAccess Free Blast
Free
Posted in: Allogeneic, BCMA, CAR-T, CD19, Topics Nov 08 | 2023Cellectis to Present Updated Clinical Data at ASH 2023; Caribou Still Plans to Share FDA Feedback on CB-010’s Pivotal Trial in 2L LBCL by YE 2023; Cellectis and Caribou Q3 2023 Earnings SummaryAccess Free Blast
Free
Posted in: Allogeneic, Autologous, CAR-T Nov 07 | 2023Lyell and CRISPR Tx Present Novel CAR-Ts in Solid Tumors; SITC 2023 Analysis 2Access Free BlastFree
Posted in: Allogeneic, Autologous, CAR-T Nov 06 | 2023Carisma Tx Shows Initial Results from its Collaboration with Moderna; AstraZeneca Presents AZD6422’s Preclinical Development in Gastrointestinal Cancers and a Synergistic Combination of AZD074 with Enzalutamide in Prostate Cancer; SITC 2023 Analysis 1Access Free BlastFree
Posted in: Autologous, BCMA, CAR-T Nov 06 | 2023Could Abecma Receive a CHMP Positive Opinion this Week?; November’s CHMP AgendaAccess Free Blast
Free
Posted in: Allogeneic, CAR-T, CD19 Nov 03 | 2023ALLO-501A’s ALPHA2 Trial Expands to Europe and Australia; EXPAND Study to Open Enrollment in Europe; ALLO-316’s Initial Results Postponed to Early 2024; Allogene’s Q3 2023 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, TCR Nov 03 | 2023Adaptimmune Presents Positive Lete-cel and Afami-cel Data in SS and MRCLSAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19, Topics Nov 03 | 2023Obe-cel BLA Submission Remains on Track for YE 2023; YTB323 and Obe-cel to Compete on Safety in SLE; AUTO6NG’s Trial in Neuroblastoma to Be Initiated by YE 2023; Clinical Results of AUTO8 at ASH; Autolus’s Q3 2023 Earnings Call SummaryAccess Free BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.